MN33-47 是一种具有广谱抗癌活性的 Bcl-2 抑制剂、caspase-3 激活剂和 DNA 交联剂,可提高 SN-38 (MS-K87916) 的水溶性,呈剂量依赖性抑制肿瘤生长和增殖且无明显毒性,通过解除线粒体凋亡通路的抑制状态启动凋亡 (apoptosis) 程序、抑制 Topo I 活性并经泛素-蛋白酶体和自噬-溶酶体通路促进其降解,同时诱导 DNA 交联、G2/M 期细胞周期阻滞和癌细胞迁移抑制,并通过线粒体通路诱导癌细胞凋亡,可用于结直肠腺癌、宫颈腺癌、肝细胞癌、肺泡基底上皮腺癌、胃癌及结肠癌的研究。
MN33-47
产品编号: MS-S92543 分子式: C27H28Cl3N3O6 分子量: 596.89
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

MN33-47 是一种具有广谱抗癌活性的 Bcl-2 抑制剂、caspase-3 激活剂和 DNA 交联剂,可提高 SN-38 (MS-K87916) 的水溶性,呈剂量依赖性抑制肿瘤生长和增殖且无明显毒性,通过解除线粒体凋亡通路的抑制状态启动凋亡 (apoptosis) 程序、抑制 Topo I 活性并经泛素-蛋白酶体和自噬-溶酶体通路促进其降解,同时诱导 DNA 交联、G2/M 期细胞周期阻滞和癌细胞迁移抑制,并通过线粒体通路诱导癌细胞凋亡,可用于结直肠腺癌、宫颈腺癌、肝细胞癌、肺泡基底上皮腺癌、胃癌及结肠癌的研究。

生物实验数据

生物活性 MN33-47 is a Bcl-2 inhibitor, caspase-3 activator, and DNA cross-linking agent with broad-spectrum anticancer activity that enhances the water solubility of SN-38 (MS-K87916), inhibits tumor growth and proliferation in a dose-dependent manner without obvious toxicity, initiates the apoptosis program by relieving the suppressed state of the mitochondrial apoptotic pathway, inhibits Topo I activity, and promotes its degradation via the ubiquitin-proteasome and autophagy-lysosome pathways; it also induces DNA cross-linking, G2/M phase cell cycle arrest, and inhibition of cancer cell migration, and induces cancer cell apoptosis through the mitochondrial pathway, and can be used for research on colorectal adenocarcinoma, cervical adenocarcinoma, hepatocellular carcinoma, alveolar basal epithelial adenocarcinoma, gastric cancer, and colon cancer.
IC50 & Target

Topoisomerase I

 

Caspase 3

 

Bcl-2

 

体外研究
(In Vitro)

MN33-47 (0.038-100000 nM; 72 h) 可强效抑制 HCT-15、HeLa、HepG2、A549、HGC-27 和 CT26 细胞的增殖,IC50=4.77-252.10 nM,与对照处理相比,对 HeLa、HepG2 和 CT26 细胞的活性更强。
MN33-47 (100 nM; 24, 48 h) 可在 24 h 和 48 h 时显著抑制 CT26 细胞的迁移,其疗效优于单药 chlormethine hydrochloride (MS-M01996) (CH) 或 SN-38 (MS-K87916)。
MN33-47 (100 nM; 48 h) 可在 48 h 后诱导 46.3% 的 CT26 细胞发生 G2/M 期阻滞,其细胞周期阻滞作用强于 CH、SN-38 或它们的物理混合物。
MN33-47 (100 nM; 48 h) 可在 48 h 后诱导 50.63% 的 CT26 细胞发生凋亡,其促凋亡功效显著优于 CH、SN-38 或它们的物理混合物。
MN33-47 (1-10000 nM, 1 μM; 72 h) 可通过泛素-蛋白酶体和自噬-溶酶体通路剂量依赖性降低 CT26 细胞中的 Topo I 蛋白水平;且在 1 μM 浓度下,其下调 Bcl-2 和激活 caspase-3 的效果优于 SN-38、CH 或二者的物理混合物。

Cell Proliferation Assay

Cell Line: HCT-15, HeLa, HepG2, A549, HGC-27, CT26
Concentration: 0.038-100000 nM
Incubation Time: 72 h
Result: Exhibited broad-spectrum antiproliferative activity across all six cell lines, with IC50 values of 8.06 nM (HCT-15), 24.43 nM (HeLa), 6.24 nM (HepG2), 252.10 nM (A549), 34.55 nM (HGC-27), and 4.77 nM (CT26).
Showed superior potency to control groups including SN-38, CH, and their physical mixture in select cell lines, with significantly enhanced inhibition against HeLa, HepG2, and CT26 cells compared to MN33-45.

Cell Cycle Analysis

Cell Line: CT26
Concentration: 100 nM
Incubation Time: 48 h
Result: Induced substantial G2/M phase arrest in CT26 cells, with 46.3% of cells in the G2/M phase, compared to 8.98% in the untreated control group.
Showed a significantly stronger arrest than that induced by CH, SN-38, or their physical mixture.

Apoptosis Analysis

Cell Line: CT26
Concentration: 100 nM
Incubation Time: 48 h
Result: Induced an apoptosis rate of 50.63% in CT26 cells, which was significantly higher than the rates induced by CH (15.91%), SN-38 (25.00%), or their physical mixture (38.20%).

Western Blot Analysis

Cell Line: CT26
Concentration: 1-10000 nM (72 h incubation); 1 μM (72 h incubation)
Incubation Time: 72 h
Result: Reduced Topo I protein levels in a dose-dependent manner, with the strongest inhibition observed at 10 μM.
At 1 μM, inhibited Topo I expression more effectively than SN-38, CH, or their physical mixture.
Downregulated Bcl-2 expression and reduced total caspase-3 protein levels (indicating activation of caspase-3) more strongly than control groups at 1 μM.
The reduction in Topo I levels induced by MN33-47 was reversed by the proteasome inhibitor MG132 and autophagy-lysosome inhibitor chloroquine.
体内研究
(In Vivo)

MN33-47 (1.56-6.24 mg/kg;腹腔注射;每日一次;连续 10 天) 在荷 CT26 肿瘤的 BALB/c 小鼠中展现出剂量依赖性的强效抗肿瘤活性,在 6.24 mg/kg 的高剂量下达到 75.73% 的肿瘤抑制率,且未观察到全身毒性或器官损伤。

Animal Model: BALB/c mice with Colon cancer (female, 4-5 weeks old, 19-21 g, subcutaneous colon cancer xenograft)
Dosage: 1.56 mg/kg; 3.12 mg/kg; 6.24 mg/kg
Administration: i.p.; daily; 10 days
Result: Achieved a tumor inhibition rate of 75.73% in the 6.24 mg/kg group.
Showed dose-dependent tumor growth inhibition.
Reduced tumor volume markedly in all dose groups compared to vehicle control, with the high-dose group having the smallest tumor mass.
Induced dose-dependent increases in tumor necrotic areas, reduced tumor cell density, and nuclear condensation, with the high-dose group showing the most pronounced effects.
Caused no significant body weight loss in any dose group.
Maintained serum ALT, AST, BUN, and CREA levels within normal reference ranges in all dose groups.
Showed no significant pathological alterations in heart, liver, spleen, lung, and kidney tissues in any dose group.

化学信息

分子量 596.89
分子式 C27H28Cl3N3O6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础